USDA, Agricultural Research Service, Beltsville Human Nutrition Research Center, Beltsville, MD 20705, USA.
Adv Nutr. 2011 Jul;2(4):332-54. doi: 10.3945/an.111.000521. Epub 2011 Jun 28.
There are 2 predominant sources of dietary trans fatty acids (TFA) in the food supply, those formed during the industrial partial hydrogenation of vegetable oils (iTFA) and those formed by biohydrogenation in ruminants (rTFA), including vaccenic acid (VA) and the naturally occurring isomer of conjugated linoleic acid, cis-9, trans-11 CLA (c9,t11-CLA). The objective of this review is to evaluate the evidence base from epidemiological and clinical studies to determine whether intake of rTFA isomers, specifically VA and c9,t11-CLA, differentially affects risk of cardiovascular disease (CVD) and cancer compared with iTFA. In addition, animal and cell culture studies are reviewed to explore potential pro- and antiatherogenic mechanisms of VA and c9,t11-CLA. Some epidemiological studies suggest that a positive association with coronary heart disease risk exists between only iTFA isomers and not rTFA isomers. Small clinical studies have been conducted to establish cause-and-effect relationships between these different sources of TFA and biomarkers or risk factors of CVD with inconclusive results. The lack of detection of treatment effects reported in some studies may be due to insufficient statistical power. Many studies have used doses of rTFA that are not realistically attainable via diet; thus, further clinical studies are warranted. Associations between iTFA intake and cancer have been inconsistent, and associations between rTFA intake and cancer have not been well studied. Clinical studies have not been conducted investigating the cause-and-effect relationship between iTFA and rTFA intake and risk for cancers. Further research is needed to determine the health effects of VA and c9,t11-CLA in humans.
饮食反式脂肪酸(TFA)有 2 个主要来源,即植物油工业部分氢化过程中形成的 TFA(iTFA)和反刍动物生物氢化过程中形成的 TFA(rTFA),包括瘤胃酸(VA)和天然存在的共轭亚油酸异构体,顺-9,反-11 CLA(c9,t11-CLA)。本综述的目的是评估来自流行病学和临床研究的证据基础,以确定 rTFA 异构体(特别是 VA 和 c9,t11-CLA)的摄入量是否与 iTFA 相比会对心血管疾病(CVD)和癌症风险产生不同的影响。此外,还回顾了动物和细胞培养研究,以探讨 VA 和 c9,t11-CLA 的潜在促动脉粥样硬化和抗动脉粥样硬化机制。一些流行病学研究表明,只有 iTFA 异构体与冠心病风险之间存在正相关,而 rTFA 异构体则没有。已经进行了一些小型临床研究,以建立这些不同来源的 TFA 与 CVD 生物标志物或风险因素之间的因果关系,但结果尚无定论。一些研究报告缺乏治疗效果可能是由于统计效力不足。许多研究使用的 rTFA 剂量在饮食中是无法实际达到的;因此,需要进一步的临床研究。iTFA 摄入量与癌症之间的关联一直不一致,rTFA 摄入量与癌症之间的关联也没有得到很好的研究。尚未进行临床研究来调查 iTFA 和 rTFA 摄入量与癌症风险之间的因果关系。需要进一步的研究来确定 VA 和 c9,t11-CLA 在人类中的健康影响。